Market Cap (In TWD)
4.06 Billion
Revenue (In TWD)
109.9 Million
Net Income (In TWD)
-156.32 Million
Avg. Volume
239.25 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 31.4-42.3
- PE
- -
- EPS
- -
- Beta Value
- 0.619
- ISIN
- TW0006733009
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Prof. Te-Li Chen M.D., Ph.D.
- Employee Count
- -
- Website
- https://www.biogend.com
- Ipo Date
- 2019-06-18
- Details
- BioGend Therapeutics Co., Ltd. develops regenerative bio-orthopaedic products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was founded in 2016 and is based in Taipei, Taiwan.
More Stocks
-
GKOSGlaukos Corporation
GKOS
-
SONN
-
600523
-
603680KTK Group Co., Ltd.
603680
-
EXICOMExicom Tele-Systems Limited
EXICOM
-
HLG
-
RKDL
-
0LFSToll Brothers, Inc.
0LFS